Pure Bioscience (PURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 07/31
| 10-2023 | 07-2023 | 04-2023 | 01-2023 | 10-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,515 | 1,170 | 856 | 1,560 | 2,527 |
| Receivables | 347 | 285 | 188 | 156 | 252 |
| Inventories | 104 | 88 | 149 | 200 | 239 |
| TOTAL | $2,066 | $1,604 | $1,230 | $1,940 | $3,072 |
| Non-Current Assets | |||||
| PPE Net | 184 | 221 | 594 | 590 | 627 |
| TOTAL | $184 | $221 | $594 | $590 | $627 |
| Total Assets | $2,250 | $1,825 | $1,824 | $2,530 | $3,699 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 652 | 422 | 432 | 347 | 561 |
| Accrued Expenses | 154 | 110 | 137 | 116 | 138 |
| TOTAL | $806 | $532 | $569 | $463 | $699 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,827 | 1,021 | N/A | N/A | N/A |
| TOTAL | $1,827 | $1,021 | $N/A | $N/A | $N/A |
| Total Liabilities | $2,633 | $1,553 | $569 | $463 | $699 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 111,857 | 111,857 | 111,357 | 111,357 | 111,357 |
| Common Shares | 1,119 | 1,119 | 1,114 | 1,114 | 1,114 |
| Retained earnings | -133,980 | -133,245 | -132,213 | -131,337 | -130,277 |
| TOTAL | $-383 | $272 | $1,255 | $2,067 | $3,000 |
| Total Liabilities And Equity | $2,250 | $1,825 | $1,824 | $2,530 | $3,699 |